Goldman Sachs’s Mateon Therapeutics MATN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
– Sell
-27,151
Closed -$17K – 7267
2016
Q3
$17K Buy
27,151
+14,199
+110% +$9.6K ﹤0.01% 6801
2016
Q2
$9K Buy
+12,952
New +$9.17K ﹤0.01% 6877

Other funds holding MATN

Goldman Sachs's MATN Position: Q4 2016 in Review

Goldman Sachs sold out of Mateon Therapeutics (MATN) in Q4 2016, closing a stake of 27,151 shares — an estimated $17K sold.

Goldman Sachs first reported a position in MATN in Q2 2016 and held it in 2 quarters. The position peaked at $17K in Q3 2016. 1 fund tracked by Wall St. Rank holds MATN as of Q4 2016.

  • Goldman Sachs reported no remaining Mateon Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Goldman Sachs sold 27,151 Mateon Therapeutics shares in Q4 2016, an estimated $17K.
  • Goldman Sachs first reported a position in Mateon Therapeutics in Q2 2016 and held it in 2 quarters.
  • Goldman Sachs's Mateon Therapeutics position peaked at $17K in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Mateon Therapeutics as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.